News | May 08, 2019

Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease

Study finds cardiac ablation reduces risk for dementia and stroke in patients with both conditions better than medication

Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease

May 8, 2019 — Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it may be a good idea for those who suffer from both atrial fibrillation and heart disease.

In a new study from the Intermountain Healthcare Heart Institute in Salt Lake City, researchers found that performing catheter ablations on patients who suffer from both atrial fibrillation and carotid arterial disease reduces their risk of dementia and stroke compared to managing their care with medications.

Catheter ablation is a procedure that makes small scars in heart tissue to prevent abnormal electrical signals from causing rapid and irregular heart rhythms, or atrial fibrillation.

The findings could lead to changes in how patients with atrial fibrillation and carotid arterial disease are treated, even if they traditionally have not been candidates for more aggressive treatment, such as an ablation.

“Often in medicine, higher-risk patients are less often referred for an invasive procedure due to concerns of procedural risk,” said T. Jared Bunch, M.D., principal investigator of the study and medical director of Heart Rhythm Services for Intermountain Healthcare. “Our research shows that higher risk patients may be those who are most likely to benefit from ablation when the procedure can be performed safely in centers with expertise so that these patients’ long-term risk of dementia and stroke can be positively impacted.”

Results of the study were presented at the American College of Cardiology (ACC) Scientific Sessions, March 16-18 in New Orleans.

“Atrial fibrillation and dementia are two disease states that are becoming more common in our society and are placing an increasing burden on patients, families and the healthcare system,” said Bunch. “The results of our study raise the awareness of the significant connection between the two and show what a significant difference catheter ablation can make as we understand the potential benefits of restoring a normal heart rhythm to improve brain health.”

In the study, researchers identified 5,786 atrial fibrillation patients with no history of dementia. Patients were then separated into those who had carotid arterial disease, and those who did not.

Researchers found that performing catheter ablation to correct irregular heartbeats in patients with both atrial fibrillation and carotid arterial disease resulted in a lower five-year risk of dementia or stroke and dementia alone, compared to similar patients who did not have the procedure done. They also found that ablation made less of a difference in patients with just atrial fibrillation.

“We have previously shown the both atrial fibrillation and carotid arterial disease can increase risk of both stroke and dementia, the next step was to understand how treatments may impact risks,” added Bunch.

Bunch believes that atrial fibrillation, which is an irregular heartbeat that leads to interrupted blood flow to the brain, is compounded by carotid arterial disease, in which plaque builds up in the carotid arteries. That’s because when an artery is blocked, the brain loses some of its ability to compensate for hemodynamic stress that can occur with abnormal heart rhythms, and as a consequence brain injury and dysfunction can develop.

“There’s not a known therapy that changes the natural progressive course of dementia.  Dementia now is one of the most common causes of disability and death in developed countries. As a consequence, we have to identify people at risk of dementia earlier before they come into the clinic with cognitive decline to start potential disease altering therapies very early,” said Bunch. “Without treatments that can improve dementia progression, our efforts need to center on prevention within the multiple pathways that cause brain injury and dysfunction.”

Study funding was provided, in part, by donors to the Intermountain Research and Medical Foundation.

For more information: www.acc.org


Related Content

News

Oct. 24, 2024 — Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera ...

Home October 30, 2024
Home
News

Oct. 18, 2024 — Boston Scientific Corp. recently announced it has received U.S. Food and Drug Administration (FDA) ...

Home October 21, 2024
Home
News

May 15, 2024 —CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac ...

Home May 15, 2024
Home
News

May 13, 2024 — Innovative Health, Inc. announced that recent growth in single-use device reprocessing has delivered ...

Home May 13, 2024
Home
News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
Subscribe Now